Serina Therapeutics (SER) awards 69,000 stock options to Chief Scientific Officer

Rhea-AI Filing Summary

Serina Therapeutics, Inc. reported an insider equity award to its Chief Scientific Officer, Randall Moreadith. On February 3, 2026, he received a grant of 69,000 stock options with an exercise price of $2.76 per share, each option linked to one share of common stock.

The options were granted at no cost to him and are held as direct ownership. According to the vesting terms, 12/48ths of the options vest 12 months after the vesting commencement date, and the remaining portion vests in equal monthly installments of 1/48th until fully vested. After this grant, he beneficially owns 69,000 derivative securities in the form of these options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moreadith Randall

(Last) (First) (Middle)

601 GENOME WAY, SUITE 2001

(Street)

HUNTSVILLE AL 35806

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.76	02/03/2026		A		69,000		(1)	02/03/2036	Common Stock	69,000	$0	69,000	D

Explanation of Responses:

1. Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested.

Remarks:

	/s/ Randall Moreadith	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Serina Therapeutics (SER) report for Randall Moreadith?

Serina Therapeutics reported a stock option grant to Chief Scientific Officer Randall Moreadith. On February 3, 2026, he was awarded 69,000 stock options, each tied to one share of common stock, as part of his equity compensation.

What are the key terms of the 69,000 stock options granted by Serina Therapeutics (SER)?

The options have a $2.76 exercise price per share and relate to 69,000 shares of common stock. They were granted at no cost to the officer, and he directly owns all 69,000 derivative securities following the reported transaction.

How do the Serina Therapeutics (SER) stock options granted to Randall Moreadith vest?

The options vest over a four-year schedule. 12/48ths of the shares vest 12 months after the vesting commencement date, and the remaining 36/48ths vest in equal monthly installments of 1/48th each month until fully vested.

What is the ownership status of the Serina Therapeutics (SER) options after the grant?

After the grant, 69,000 derivative securities are beneficially owned by Randall Moreadith. These securities are held as direct ownership and represent stock options with rights to buy Serina Therapeutics common stock at the stated exercise price.

What role does Randall Moreadith hold at Serina Therapeutics (SER) in this Form 4 filing?

Randall Moreadith is the Chief Scientific Officer of Serina Therapeutics. The Form 4 filing reports a grant of stock options to him in his capacity as an officer, documenting the acquisition and vesting terms of this equity award.